Looking for a surefire wealth builder? Open a Roth IRA. You fund this retirement account with after-tax dollars, so the pain is up front. The payoff? All withdrawals are tax-free if youre at least 59陆 and have held the account for at least five years. You can always withdraw your original contributions tax- and penalty-free.
See Also: 10 Financial Decisions You Will Regret in Retirement
With traditional IRAs and 401(k)s, you have to take required minimum distributions every year. Not so with a Roth — you can withdraw money strategically. Or, you can just let it grow and leave it to your heirs. And because withdrawals from a Roth arent reported to the IRS as income, they wont increase the taxes on your Social Security benefits. Roth withdrawals also wont trigger the high-income surcharge on Medicare Part B or Part D.
Top Financial Stocks For 2018: LINE Corporation (LN)
Advisors’ Opinion:
- [By Seth McNew]
Shares of the Japanese messaging and increasingly social media-like company Line Corp.(NYSE:LN)took a hit today, falling nearly 12% at one point today, even though the company reported a strong rise in sales for its first quarter and positive results from its new features.
- [By Wayne Duggan]
In addition to DianDianChong, Japanese company Line Corp (ADR) (NYSE: LN) holds a nearly 50 percent stake in a South Korean Snapchat clone called Snow. Line’s recent $45 million investment in Snow values the company at around $207 million compared to Snap’s $24.8 billion market cap. Snow currently has 40 million–50 million active users, less than a third of Snapchat’s audience. Snow’s app also features familiar face filters and disappearing messages.
Top Financial Stocks For 2018: Jazz Pharmaceuticals Inc.(JAZZ)
Advisors’ Opinion:
- [By Keith Speights]
In December, I included Jazz Pharmaceuticals (NASDAQ:JAZZ) in a list of the three top healthcare stocks investors were overlooking. At that time, I noted that the biotech stock could be a diamond in the rough with its promising pipeline and low valuation.
- [By Benzinga News Desk]
On Wednesday, just 24 hours after Amazon announced its first major sports deal — tying up with the NFL to stream 10 Thursday night games — Alphabet Inc (NASDAQ: GOOGL) laid claim to viewers’ credit cards by debuting YouTube TV, a bundle of 50 major television channels for $35 per month: Link
ECONOMIC DATA
March 2017 US Challenger layoffs report 43,310 vs 36,975
Initial Jobless Claims for Mar 31 234.0K vs 250.0K estimate; Continuing Claims for Mar 24 2.03M vs 2.04M estimate.
San Francisco Federal Reserve Bank President John Williams is set to speak in Frankfurt at 9:30 a.m. ET.
The Energy Information Administration’s weekly report on natural gas stocks is schedule for release at 10:30 a.m. ET.
Data on money supply for the recent week will be released at 4:30 p.m. ET.
ANALYST RATINGS
Goldman Sachs initiated Advanced Micro Devices (NASDAQ: AMD) at Sell
JMP Securities upgraded NetApp (NASDAQ: NTAP) from Market Underperform to Market Perform
PiperJaffray upgraded Abiomed (NASDAQ: ABMD) from Neutral to Overweight
Deutsche Bank downgraded T-Mobile (NASDAQ: TMUS) from Buy to Hold
Mizuho downgraded Jazz Pharmaceuticals (NASDAQ: JAZZ) from Buy to Neutral
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here or email minutes@benzinga.com.
- [By Teresa Rivas]
Jazz Pharmaceuticals (JAZZ) is trading up nearly 9% Thursday, thanks to its settlement with Hikma Pharmaceuticals over the firms patent dispute.
Pixabay
As part of the agreement, Hikma will get to sell a generic version of the drug in question, narcolepsy treatment Xyrem, in 2023, for up to five years, while Jazz will get royalties on those sales.
Janney Montgomery Scotts Ken Trbovich upgraded the shares from Neutral to Buy on the news, and also increased his price target from $138 to $175. From his note:
While this comes about three years earlier than previous settlements with other generic filers, it eliminates the risk of an earlier launch. Six months thereafter Hikma may launch its own generic and others may potentially be able to launch as well. Importantly, Jazz will receive a meaningful royalty on sales, retain the right to launch its own AG, and can authorize other AGs after the initial 6-month Hikma period.
Jazz shares are up 8.9% to $153.2o at recent check.
- [By Lisa Levin] Gainers
Trevena Inc (NASDAQ: TRVN) rose 10.8 percent to $3.60 in pre-market trading after dropping 4.97 percent on Wednesday.
Yum China Holdings Inc (NYSE: YUMC) rose 10.2 percent to $31.05 in pre-market trading after the company reported upbeat earnings for its first quarter.
Seres Therapeutics Inc (NASDAQ: MCRB) rose 9.1 percent to $11.39 in pre-market trading after dropping 5.26 percent on Wednesday.
Plug Power Inc (NASDAQ: PLUG) rose 8.9 percent to $2.45 in pre-market trading after surging 73.08 percent on Wednesday.
Coach Inc (NYSE: COH) rose 6.7 percent to $41.98 in pre-market trading. Coach named Ian Bickley as President, Global Business Development and Strategic Alliances.
Sapiens International Corporation N.V. (NASDAQ: SPNS) shares rose 6.1 percent to $13.91 in pre-market trading after gaining 0.54 percent on Wednesday.
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) rose 6.1 percent to $149.15 in pre-market trading. Jazz Pharma reached a settlement with Hikma Pharma related to Xyrem patent case. Mizuho downgraded Jazz from Buy to Neutral.
Interactive Brokers Group, Inc. (NASDAQ: IBKR) shares rose 6 percent to $36.72 in pre-market trading after declining 0.03 percent on Wednesday.
Rewalk Robotics Ltd (NASDAQ: RWLK) rose 5.3 percent to $2.00 in pre-market trading after the company disclosed that the U.S. Department of Veterans Affairs purchased 28 added Exoskeleton Systems.
Merrimack Pharmaceuticals Inc (NASDAQ: MACK) rose 5.1 percent to $3.29 in pre-market trading. Merrimack declared a $1.06 special dividend.
BioTime, Inc. (NYSE: BTX) shares rose 4.8 percent to $3.50 in pre-market trading. BioTime, reported the formation of new subsidiary AgeX Therapeutics, Inc.
Akari Therapeutics PLC (ADR) (NASDAQ: AKTX) shares rose 4.8 percent to $12.26 in pre-market trading after gaining 0.69 percent on Wednesday.
Bed Bath & Beyond Inc. (NASDAQ: BBBY) rose 3.6 percent to $39.15 in pre-market trading after the company posted better-than - [By Jim Robertson]
The earnings report summarized the following recent milestones:
The formation of a Scientific Advisory Board (SAB) to provide expert guidance and insight as the Company advances towards product commercialization. in October, Pfenex announced the hiring of Steven Sandoval as Chief Manufacturing Officer.Steven has over 25 years of commercial biopharmaceutical engineering and operations experience, specializing in commercial operations, facility design and licensure of large scale biopharmaceutical commercial manufacturing facilities. Following the announcement in August of the positive Phase 1 trial data for Pfenex’s recombinant anthrax vaccine, discussions with BARDA have been progressing. Pfenex anticipates initiating the PF708 pivotal clinical program by year end. Pfenex entered into a collaboration with Jazz Pharmaceuticals plc (NASDAQ: JAZZ) on multiple hematology/oncology product candidates in July. Regulatory feedback for PF529, Pfenex’s biosimilar candidate to Neulasta (pegfilgrastim), is expected by the end of 2016 and following that feedback, the development path and potential timeline will be outlined.
Do you like this trading idea and want more trading setups delivered to you every day? Consider investing in a subscription to our SmallCap Network Elite Opportunity (SCN EO) portfolio newsletter or our Under the Radar Movers newsletter where you’ll get more and even better trading setups, investing ideas or tips.
Top Financial Stocks For 2018: Cara Therapeutics, Inc.(CARA)
Advisors’ Opinion:
- [By Javier Hasse]
On the other hand, Cara Therapeutics Inc (NASDAQ: CARA) was up almost 1.9 percent in what also looked like a correction of the 1.6 percent gain registered over the regular trading session.
- [By WWW.THESTREET.COM]
In the Lightning Round, Cramer was bullish on Cara Therapeutics (CARA) , Verizon (VZ) , Radius Health (RDUS) and Six Flags (SIX) .
Cramer was bearish on Hertz Global Holdings (HTZ) , General Motors (GM) , Pandora Media (P) , Cedar Fair (FUN) , Quotient Technology (QUOT) and Rite Aid (RAD) .
